ライフサイエンスコーパス: angiotensin-converting enzyme

1 ly inhibition of dipeptidyl peptidase IV and angiotensin-converting enzyme.

2 The angiotensin converting enzyme-1-angiotensin II-angiotens

3 poglycorrhachia (11%, p = 0.25) and elevated angiotensin-converting enzyme (18%, p = 0.30) were exclu

4 protein to bind to the cell surface receptor angiotensin converting enzyme 2 (ACE2) glycoprotein and

5 ion occurs through binding of the virus with angiotensin converting enzyme 2 (ACE2) on the cell membr

6 Angiotensin converting enzyme 2 (ACE2) plays an importan

7 and block spike protein interaction with the angiotensin converting enzyme 2 (ACE2) with 1-5 nM affin

8 moke causes a dose-dependent upregulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 r

9 is brief perspective, we examine the role of angiotensin converting enzyme 2 as the receptor for seve

10 The role of angiotensin converting enzyme 2 has expanded from regula

11 Recently, angiotensin converting enzyme 2 was identified as a prim

12 on with enhanced BP, decreased expression of angiotensin converting enzyme 2, and increased expressio

13 The counter-regulatory axis, Angiotensin Converting Enzyme 2, Angiotensin-(1-7), Mas

14 protein with approximately 50% homology with angiotensin converting enzyme 2, but without a catalytic

15 soluble forms of the receptor for the virus, angiotensin converting enzyme 2.

16 Angiotensin-converting enzyme 2 (ACE-2), neprilysin (NEP

17 main (RBD) showing crucial interactions with angiotensin-converting enzyme 2 (ACE2) and cross-reactin

18 Angiotensin-converting enzyme 2 (ACE2) and its product,

19 s critical for SARS-CoV-2 infection, namely, angiotensin-converting enzyme 2 (ACE2) and transmembrane

20 ausing COVID-19, is facilitated by host cell angiotensin-converting enzyme 2 (ACE2) and transmembrane

21 SARS-CoV-2 and the human cellular receptor, angiotensin-converting enzyme 2 (ACE2) are both densely

22 SARS-CoV-2 uses human angiotensin-converting enzyme 2 (ACE2) as its receptor t

23 Early evidence pointed to angiotensin-converting enzyme 2 (ACE2) as SARS-CoV-2 ent

24 how that S2E12 and S2M11 competitively block angiotensin-converting enzyme 2 (ACE2) attachment and th

25 ity RNA in situ mapping revealed the highest angiotensin-converting enzyme 2 (ACE2) expression in the

26 coronaviruses to utilize animal orthologs of angiotensin-converting enzyme 2 (ACE2) for cell entry.

27 SARS-CoV-2), which causes COVID-19, utilizes angiotensin-converting enzyme 2 (ACE2) for entry into ta

28 This study compares angiotensin-converting enzyme 2 (ACE2) gene expression,

29 Angiotensin-converting enzyme 2 (ACE2) has been identifi

30 locked S conformation, resulting in reduced angiotensin-converting enzyme 2 (ACE2) interaction in vi

31 Angiotensin-converting enzyme 2 (ACE2) is a potent negat

32 Angiotensin-converting enzyme 2 (ACE2) is an entry recep

33 SARS-CoV-2 spike protein binding to angiotensin-converting enzyme 2 (ACE2) is critical for v

34 Although angiotensin-converting enzyme 2 (ACE2) is crucial for SA

35 In particular, activity of the angiotensin-converting enzyme 2 (ACE2) is dysregulated i

36 Angiotensin-converting enzyme 2 (ACE2) is the canonical

37 ry syndrome coronavirus 2 (SARS-CoV-2) binds angiotensin-converting enzyme 2 (ACE2) on host cells to

38 as recently reported that the human receptor angiotensin-converting enzyme 2 (ACE2) plays a key role

39 case studies were demonstrated, one being on angiotensin-converting enzyme 2 (ACE2) protein which is

40 e novel coronavirus canonically utilizes the angiotensin-converting enzyme 2 (ACE2) receptor and the

41 RBD) of the spike protein binds to the human angiotensin-converting enzyme 2 (ACE2) receptor as a pre

42 ining region (CDR) H3, and competes with the angiotensin-converting enzyme 2 (ACE2) receptor because

43 SARS-CoV-2 spike protein and blocking to the Angiotensin-converting enzyme 2 (ACE2) receptor in a sin

44 s 2 (SARS-CoV-2) spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor is a pro

45 domain (RBD), the hexapeptide YKYRYL on the angiotensin-converting enzyme 2 (ACE2) receptor, and its

46 were engineered to stably express the human angiotensin-converting enzyme 2 (ACE2) receptor, but sta

47 action of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor.

48 use of species-specific differences in their angiotensin-converting enzyme 2 (ACE2) receptors.

49 racts with both cellular heparan sulfate and angiotensin-converting enzyme 2 (ACE2) through its recep

50 Infection of human angiotensin-converting enzyme 2 (ACE2) transgenic mice a

51 evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affin

52 the mouse orthologue of the human receptor, angiotensin-converting enzyme 2 (ACE2)(4).

53 SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert w

54 2) virus enters host cells by binding to the angiotensin-converting enzyme 2 (ACE2), but whether or n

55 - SARS-CoV-2 - gains entry to host cells via angiotensin-converting enzyme 2 (ACE2), highlighting the

56 re acute respiratory syndrome coronavirus 2, angiotensin-converting enzyme 2 (ACE2), is highly expres

57 onavirus 2 (SARS-CoV-2) viral association to angiotensin-converting enzyme 2 (ACE2), its main host re

58 in is a candidate vaccine antigen that binds angiotensin-converting enzyme 2 (ACE2), leading to virus

59 s, we demonstrate that, in addition to human angiotensin-converting enzyme 2 (ACE2), the Spike glycop

60 The receptor for SARS-CoV-2 binding, angiotensin-converting enzyme 2 (ACE2), was not detected

61 r-binding domain (RBD) and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate b

62 SARS-CoV spike protein and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate b

63 lar localization of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), within the upper

64 V-2 and SARS-CoV recognize the same receptor-angiotensin-converting enzyme 2 (ACE2)-in humans(3,4).

65 izes an epitope that partially overlaps with angiotensin-converting enzyme 2 (ACE2)-interacting sites

66 19 (Covid-19), because the viral receptor is angiotensin-converting enzyme 2 (ACE2).

67 its Spike protein and the host cell receptor angiotensin-converting enzyme 2 (ACE2).

68 SARS-CoV-2 binds to its receptor, the angiotensin-converting enzyme 2 (ACE2).

69 ost cell infection is mediated by binding to angiotensin-converting enzyme 2 (ACE2).

70 protein (S(RBD)) from interacting with human angiotensin-converting enzyme 2 (ACE2).

71 ted coronavirus (SARS-CoV-2) that uses human angiotensin-converting enzyme 2 (hACE2) as the entry rec

72 e show that transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) by the human cyt

73 alidation, and optimization of de novo human angiotensin-converting enzyme 2 (hACE2) decoys to neutra

74 In response to human receptor angiotensin-converting enzyme 2 (hACE2), S opens sequent

75 mouse orthologue of its human entry receptor angiotensin-converting enzyme 2 (hACE2).

76 The conversion is catalyzed by angiotensin-converting enzyme 2 and other enzymes that s

77 domain (RBD) are compared with those between angiotensin-converting enzyme 2 and RBD complexes.

78 han SARS-CoV according to computed S protein-angiotensin-converting enzyme 2 binding free energy chan

79 Arteriolar angiotensin-converting enzyme 2 endothelial expression w

80 an alternate viral illness; (3) investigate angiotensin-converting enzyme 2 expression; and (4) prov

81 An angiotensin-converting enzyme 2 immunohistochemical H-sc

82 r by adsorptive transcytosis and that murine angiotensin-converting enzyme 2 is involved in brain and

83 was lower in fetal growth restriction in an angiotensin-converting enzyme 2 knockout mouse model cha

84 Angiotensin-converting enzyme 2 myocardial expression di

85 Heavily glycosylated S trimers bind to the angiotensin-converting enzyme 2 receptor and mediate ent

86 s the interplay between virus binding to the angiotensin-converting enzyme 2 receptor and the impact

87 oV-2 spike glycoprotein (S protein) and host angiotensin-converting enzyme 2 receptor following mutat

88 f its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and air

89 ronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor.

90 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor.

91 Although angiotensin-converting enzyme 2 serves as the portal for

92 Human angiotensin-converting enzyme 2(ACE2) was identified as

93 ACE2 (angiotensin-converting enzyme 2) and Ang 1-7 (angiotensi

94 ACE2 (angiotensin-converting enzyme 2) and NEP (neprilysin) in

95 2 infection is binding of the virus to ACE2 (angiotensin-converting enzyme 2) on the airway epitheliu

96 ACE2 (angiotensin-converting enzyme 2), and TMPRSS2 (transmemb

97 CoV-2 to invade endothelial cells via ACE-2 (angiotensin-converting enzyme 2), which is expressed on

98 Background Angiotensin-converting enzyme 2, a target of severe acut

99 ose receptor binding domain (RBD) recognizes angiotensin-converting enzyme 2, initiating conformation

100 inent effects on host proteins, most notably angiotensin-converting enzyme 2, might also provide wort

101 ally, NETs triggered by SARS-CoV-2 depend on angiotensin-converting enzyme 2, serine protease, virus

102 onsists of angiotensin 1-7, angiotensin 1-9, angiotensin-converting enzyme 2, the type 2 angiotensin

103 ke protein trimer immunoglobulin G inhibited angiotensin-converting enzyme 2-spike protein binding to

104 ngiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme 2.

105 hin its trimeric spike glycoprotein to human angiotensin-converting enzyme 2.

106 n system, angiotensin-converting enzyme, and angiotensin-converting enzyme 2.

107 red by binding of the viral spike protein to angiotensin-converting enzyme 2.

108 a to inhibit the binding of spike protein to angiotensin-converting enzyme 2.

109 ion of the functional receptor of the virus, angiotensin-converting enzyme 2.

110 The discovery of angiotensin converting enzyme-2 (ACE-2) as the receptor

111 2, the pathogenic agent of COVID-19, employs angiotensin converting enzyme-2 (ACE2) as its cell entry

112 nt parameters to identify factors related to angiotensin-converting enzyme-2 (ACE2) expression within

113 In this paper, we report that angiotensin-converting enzyme-2 (ACE2) protected against

114 e receptor binding domain that engages human angiotensin-converting enzyme-2 (ACE2).

115 ssion of the SARS-CoV-2 viral entry receptor angiotensin-converting enzyme-2 (ACE2).

116 Angiotensin-converting-enzyme-2 (ACE2) has been describe

117 st cells through direct interaction with the angiotensin converting enzyme (ACE) 2 protein at the sur

118 olic arterial pressure and 19% inhibition of angiotensin converting enzyme (ACE) activity.

119 olase PP for 1h (STP-C1) had the most potent angiotensin converting enzyme (ACE) and dipeptidyl pepti

120 Angiotensin Converting Enzyme (ACE) Inhibitor treatment

121 lure with reduced ejection fraction, such as angiotensin converting enzyme (ACE) inhibitors, angioten

122 e Pinto bean peptides with alpha-amylase and angiotensin converting enzyme (ACE) inhibitory activitie

123 Three angiotensin converting enzyme (ACE) inhibitory peptides,

124 hophysiology has been proposed: imbalance of angiotensin converting enzymes (ACE)1 and ACE2 (ACE2 bei

125 ignificant changes in serum, lung and kidney angiotensin-converting enzyme (ACE) activity, establishe

126 Angiotensin-converting enzyme (ACE) affects blood pressu

127 Neprilysin (NEP) and angiotensin-converting enzyme (ACE) are two key zinc-dep

128 Angiotensin-converting enzyme (ACE) can hydrolyze many p

129 Angiotensin-converting enzyme (ACE) converts angiotensin

130 Angiotensin II, converted by angiotensin-converting enzyme (ACE) from angiotensin I a

131 d how prior HF history and treatment with an angiotensin-converting enzyme (ACE) inhibitor or angiote

132 To assess the effect of early angiotensin-converting enzyme (ACE) inhibitor therapy in

133 n reported to decrease time-to-resolution of angiotensin-converting enzyme (ACE) inhibitor-associated

134 The top three most common medications were angiotensin-converting enzyme (ACE) inhibitors (17.9%),

135 F) beyond conventional therapy consisting of angiotensin-converting enzyme (ACE) inhibitors or angiot

136 goal of this study was to determine whether angiotensin-converting enzyme (ACE) inhibitors or angiot

137 ew and meta-analysis to assess the effect of angiotensin-converting enzyme (ACE) inhibitors, angioten

138 Angiotensin-converting enzyme (ACE) inhibitors/angiotens

139 Targeted overexpression of angiotensin-converting enzyme (ACE), an amyloid-beta pro

140 fit heart, we measured the mRNA of renin and angiotensin-converting enzyme (ACE), and found both were

141 SNPs) at renin (REN), angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin II type

142 ipeptidase, a peptidase related to mammalian angiotensin-converting enzyme (ACE), are insecticidal to

143 sates, which are efficient inhibitors of the angiotensin-converting enzyme (ACE).

144 Genes encoding angiotensin-converting enzymes (Ace and Ace2) are essent

145 used regarding a potential harmful effect of angiotensin-converting-enzyme (ACE) inhibitors and angio

146 vels of albumin excretion might benefit from angiotensin-converting-enzyme (ACE) inhibitors and stati

147 of angiotensin-receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors and the r

148 Guideline-recommended doses of angiotensin-converting-enzyme (ACE) inhibitors or angiot

149 Among patients with chronic heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mo

150 C, carotenoids and phenolic compounds, DPPH, angiotensin-converting-enzyme (ACE) inhibitory activity,

151 ha-amylase and alpha-glucosidase inhibition, angiotensin-converting-enzyme (ACE)-inhibition, antioxid

152 GET, 25 127 patients known to be tolerant to angiotensin-converting-enzyme (ACE)-inhibitors were rand

153 tory diagnostic biomarkers (eg, lysozyme and angiotensin-converting enzyme [ACE]) are lacking in high

154 e AT2 cells express the SARS-CoV-2 receptors angiotensin converting enzyme (ACE2) and transmembrane p

155 ally representative information about use of angiotensin-converting enzyme (ACEs) inhibitors or angio

156 Members of the renin-angiotensin system-angiotensin-converting enzymes (ACEs) ACE and ACE2, angi

157 These MPs exhibited angiotensin-converting enzyme activity and upregulated A

158 ride-exposed and mechanical ventilated rats, angiotensin-converting enzyme activity in bronchoalveola

159 s in F2 neonatal offspring growth and tissue angiotensin-converting enzyme activity were programmed b

160 s of the pulmonary renin-angiotensin system, angiotensin-converting enzyme, and angiotensin-convertin

161 ified on QiShenYiQi Pills using thrombin and angiotensin converting enzyme as "quality biomarkers".

162 mic antineutrophil cytoplasmic antibody, and angiotensin-converting enzyme blood test results were ne

163 bitor (lisinopril) and thus was dependent on angiotensin-converting enzyme catalytic activity.

164 sin II by a chymase-dependent rather than an angiotensin converting enzyme-dependent mechanism.

165 in downstream signaling pathways that induce angiotensin-converting enzyme expression and endothelial

166 elevation and 20-HETE-mediated increases in angiotensin-converting enzyme expression, endothelial dy

167 cluding dipeptidyl peptidase-IV (DPP-IV) and angiotensin converting enzyme I (ACE) inhibition, glucos

168 rotein binding to the human receptor protein angiotensin-converting enzyme II (ACE2).

169 e activity and upregulated AT1 receptors and angiotensin-converting enzyme in P1 ECs.

170 l growth factor receptor phosphorylation and angiotensin-converting enzyme induction.

171 Finally, angiotensin-converting enzyme inhibition (captopril) nor

172 as been shown to be even more effective than angiotensin-converting enzyme inhibition alone in heart

173 ological functions, including antimicrobial, angiotensin-converting enzyme inhibition, antioxidant, o

174 duced residual albuminuria during fixed dose angiotensin-converting enzyme inhibition.

175 e, primary renal disease classification, and angiotensin converting enzyme inhibitor or angiotensin r

176 tes mellitus and overt nephropathy receiving angiotensin converting enzyme inhibitor or angiotensin r

177 giotensin Receptor-Neprilysin Inhibitor With Angiotensin Converting Enzyme Inhibitor to Determine Imp

178 ioedema, hereditary angioedema type III, and angiotensin converting enzyme inhibitor-induced angioede

179 f amlodipine 5 mg/day, a standard dose of an angiotensin converting enzyme inhibitor/angiotensin rece

180 There is no consensus whether angiotensin-converting enzyme inhibitor (ACEI) and angio

181 conflicting regarding whether chronic use of angiotensin-converting enzyme inhibitor (ACEI) or angiot

182 ications to medical therapy, use and dose of angiotensin-converting enzyme inhibitor (ACEI)/angiotens

183 neficial ACE10 phenotype was reversed by the angiotensin-converting enzyme inhibitor (lisinopril) and

184 Pairwise matching (1:1) of the angiotensin-converting enzyme inhibitor and angiotensin

185 ptor blockers losartan and valsartan and the angiotensin-converting enzyme inhibitor captopril on wou

186 ium oxide nanoparticles for the detection of angiotensin-converting enzyme inhibitor drug, captopril,

187 ejection fraction (HFrEF), compared with the angiotensin-converting enzyme inhibitor enalapril, and i

188 ant prevented blood pressure lowering in the angiotensin-converting enzyme inhibitor group (p < 0.001

189 lood lactate was significantly higher in the angiotensin-converting enzyme inhibitor group than in th

190 ume withdrawn was significantly lower in the angiotensin-converting enzyme inhibitor group than in th

191 -angiotensin-aldosterone pathway, such as an angiotensin-converting enzyme inhibitor or an angiotensi

192 ent with a glomerular disease with either an angiotensin-converting enzyme inhibitor or an angiotensi

193 mol), who had been receiving stable doses of angiotensin-converting enzyme inhibitor or angiotensin I

194 or without saxagliptin, given in addition to angiotensin-converting enzyme inhibitor or angiotensin I

195 ack patients and 18.2% of patients not on an angiotensin-converting enzyme inhibitor or angiotensin I

196 (<140 mm Hg systolic, <90 mm Hg diastolic), angiotensin-converting enzyme inhibitor or angiotensin r

197 arm, patients on active therapy with either angiotensin-converting enzyme inhibitor or beta-blockers

198 It is an angiotensin-converting enzyme inhibitor that operates vi

199 ia could identify patients with COPD in whom angiotensin-converting enzyme inhibitor therapy improves

200 effectiveness of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patie

201 tensin Receptor-Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Imp

202 resent findings support the possibility that angiotensin-converting enzyme inhibitor treatment might

203 rular status, birth weight, premature birth, angiotensin-converting enzyme inhibitor use, angiotensin

204 tion fraction (HFrEF), who tolerate an ACEI (angiotensin-converting enzyme inhibitor) or ARB (angiote

205 RAAS inhibition by enalapril (angiotensin-converting enzyme inhibitor) or losartan (an

206 n angiotensin receptor-neprilysin inhibitor, angiotensin-converting enzyme inhibitor, or angiotensin

207 The benefit of sacubitril/valsartan, over an angiotensin-converting enzyme inhibitor, was consistent

208 eceptor blockade during hemorrhagic shock in angiotensin-converting enzyme inhibitor-treated mice.

209 nts' baseline characteristics (shock, use of angiotensin-converting enzyme inhibitor/angiotensin II r

210 98% of patients were on >50% target dose for angiotensin-converting enzyme inhibitor/angiotensin rece

211 idence, clinical characteristics, treatment (angiotensin-converting enzyme inhibitor/angiotensin rece

212 445-patient subset received at least 1 GDMT (angiotensin-converting enzyme inhibitor/angiotensin rece

213 s a combination of statin, beta-blocker, and angiotensin-converting enzyme inhibitor/angiotensin rece

214 in Receptor-Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Im

215 in Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Im

216 he renin- angiotensin system, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angi

217 on <40% (OR, 0.97 [95% CI, 0.69-1.35]), ACE (angiotensin-converting enzyme) inhibitor or angiotensin

218 um testing within 30 days of initiating ACE (angiotensin-converting enzyme) inhibitor or angiotensin

219 vely low-cost heart failure medication (ACE [angiotensin-converting enzyme] inhibitor or angiotensin

220 Pivotal trials of beta-blockers (BB) and angiotensin converting enzyme inhibitors/angiotensin rec

221 geting the renin-angiotensin system, such as angiotensin-converting enzyme inhibitors (ACE-Is) and an

222 The association between angiotensin-converting enzyme inhibitors (ACEI) and angi

223 e first mechanistic evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angio

224 Although statins, angiotensin-converting enzyme inhibitors (ACEI) or angio

225 vestigated continued and discontinued use of angiotensin-converting enzyme inhibitors (ACEi) or angio

226 re with reduced ejection fraction, including angiotensin-converting enzyme inhibitors (ACEI), angiote

227 CI], -1.46 to -0.02; P = 0.01), specifically angiotensin-converting enzyme inhibitors (ACEIs) (beta =

228 The role of angiotensin-converting enzyme inhibitors (ACEIs) and ang

229 Angiotensin-converting enzyme inhibitors (ACEIs) may ret

230 rm use of calcium channel blockers (CCBs) or angiotensin-converting enzyme inhibitors (ACEis), respec

231 It has been hypothesized that angiotensin-converting enzyme inhibitors (ACEIs)/angiote

232 but an increased risk was found for users of angiotensin-converting enzyme inhibitors (adjusted OR 1

233 or blockers (OR = 0.70, 95% CI 0.54-0.92) or angiotensin-converting enzyme inhibitors (OR = 0.69, 95%

234 dication use (antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors [ACEIs] or angi

235 ondition for which the medication was taken (angiotensin-converting enzyme inhibitors [ACEIs], angiot

236 ere -4.38 mm Hg (95% CI, -7.27 to -2.16) for angiotensin-converting enzyme inhibitors and -3.07 mm Hg

237 100 person-years for the patients receiving angiotensin-converting enzyme inhibitors and 2.87 per 10

238 prescribed drugs in the same year, including angiotensin-converting enzyme inhibitors and angiotensin

239 This study aimed to compare the effect of angiotensin-converting enzyme inhibitors and angiotensin

240 ssessed for each of 6 drug classes: statins, angiotensin-converting enzyme inhibitors and angiotensin

241 On admission, medical therapy, including angiotensin-converting enzyme inhibitors and angiotensin

242 view that found high-certainty evidence that angiotensin-converting enzyme inhibitors and angiotensin

243 Angiotensin-converting enzyme inhibitors and beta-blocke

244 We hypothesized that angiotensin-converting enzyme inhibitors and beta-blocke

245 ons known to be unsafe in pregnancy, such as angiotensin-converting enzyme inhibitors and statins, sh

246 de or thiazide-like diuretics superiority to angiotensin-converting enzyme inhibitors and the inferio

247 Current standard therapy with angiotensin-converting enzyme inhibitors and/or angioten

248 Because the pharmacologic effects of angiotensin-converting enzyme inhibitors are partly medi

249 reduced ejection fraction (HFrEF) receiving angiotensin-converting enzyme inhibitors are well-docume

250 ation before the index date, those receiving angiotensin-converting enzyme inhibitors had a higher ri

251 In addition, the patients receiving angiotensin-converting enzyme inhibitors had a higher ri

252 Patients receiving beta-blockers or angiotensin-converting enzyme inhibitors had a higher ri

253 ith lower rates of sepsis and mortality than angiotensin-converting enzyme inhibitors in the patients

254 clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin

255 ves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin

256 e management), treatment of albuminuria (eg, angiotensin-converting enzyme inhibitors or angiotensin

257 c obstructive pulmonary disease who received angiotensin-converting enzyme inhibitors or angiotensin

258 were receiving insulin, and 84% were taking angiotensin-converting enzyme inhibitors or angiotensin

259 opathy and proteinuria >1 g/d, maintained on angiotensin-converting enzyme inhibitors or angiotensin

260 ck patients and patients with intolerance to angiotensin-converting enzyme inhibitors or angiotensin

261 sting), prescribing appropriate medications (angiotensin-converting enzyme inhibitors or angiotensin-

262 sting), prescribing appropriate medications (angiotensin-converting enzyme inhibitors or angiotensin-

263 rpose of this study was to determine whether angiotensin-converting enzyme inhibitors or beta-blocker

264 tments consider the use of beta-blockers and angiotensin-converting enzyme inhibitors that are sympto

265 m, as evidenced by trials that have compared angiotensin-converting enzyme inhibitors with drugs that

266 zine for 48 hours, and rapid up-titration of angiotensin-converting enzyme inhibitors, angiotensin re

267 classes thiazide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin re

268 No class of medications (i.e., angiotensin-converting enzyme inhibitors, angiotensin-re

269 Suitable genetic proxies for angiotensin-converting enzyme inhibitors, beta-blockers,

270 that promoted antiplatelet agents, statins, angiotensin-converting enzyme inhibitors, blood pressure

271 be prescribed lipid-lowering medication and angiotensin-converting enzyme inhibitors, especially if

272 g proportion of days covered for statins and angiotensin-converting enzyme inhibitors, patients were

273 hereas 91% and 54% were on beta-blockers and angiotensin-converting enzyme inhibitors, respectively.

274 system with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors.

275 red thiazide or thiazide-like diuretics over angiotensin-converting enzyme inhibitors.

276 ives (eOC), hormonal replacement therapy, or angiotensin-converting enzyme inhibitors.

277 Utilization of statins, beta-blockers, and angiotensin-converting enzyme inhibitors/angiotensin rec

278 al therapy including statins, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin rec

279 and 0.86 (0.74-1.01) in patients on statins, angiotensin-converting enzyme inhibitors/angiotensin rec

280 ficial effects of treatment with statins and angiotensin-converting enzyme inhibitors/angiotensin rec

281 , and 66.4% of the patients were on statins, angiotensin-converting enzyme inhibitors/angiotensin rec

282 es were treatment at discharge with statins, angiotensin-converting enzyme inhibitors/angiotensin rec

283 versus 57% in rural; P=0.1) and reversed for angiotensin-converting enzyme inhibitors/angiotensin rec

284 , documentation of ejection fraction, use of angiotensin-converting enzyme inhibitors/angiotensin rec

285 ics showed better primary effectiveness than angiotensin-converting enzyme inhibitors: acute myocardi

286 appropriate initiation of beta blockers and angiotensin-converting-enzyme inhibitors (ACE-Is) or ang

287 s a metabolite significantly associated with angiotensin-converting-enzyme inhibitors in our metabolo

288 ential introduction of medications including angiotensin-converting-enzyme inhibitors, angiotensin-re

289 in-II-antagonists, calcium-channel blockers, angiotensin-converting-enzyme inhibitors, serotonin-spec

290 rgic receptor blockers (beta-blockers), ACE (angiotensin-converting enzyme) inhibitors and ANG (angio

291 Results Combination therapy of ACE (angiotensin-converting enzyme) inhibitors or ARBs (angio

292 of them exerting relevant bioactivities like angiotensin converting enzyme inhibitory activity, antio

293 at probe mesangial cells for the presence of angiotensin-converting enzyme on their surface using ang

294 Pharmacologically antagonizing either the angiotensin-converting enzyme or the receptor for angiot

295 used to inhibit the activity of neprilysin, angiotensin-converting enzyme, or aminopeptidase N, resp

296 the first evidence for therapeutic roles of angiotensin-converting enzyme-overexpressing macrophages

297 plored the impact of selective and transient angiotensin-converting enzyme overexpression on macropha

298 syndrome coronavirus 2 (SARS-CoV-2) receptor angiotensin-converting enzyme receptor type-2 (ACE2) and

299 at it is also associated with a reduction of angiotensin-converting enzyme type 2 (ACE2) and an incre

300 One such effector was angiotensin-converting enzyme, which is a member of the